Zhang T, Lin T, Wang Y, et al. - Given that treatment with enalapril plus folic acid vs enalapril alone resulted in a significant risk reduction of the first stroke among hypertensive patients in the China Stroke Primary Prevention Trial (CSPPT), but no information has been gained regarding the lifetime stroke-free survival associated with the treatment, and therefore, researchers estimated lifetime incremental stroke-free survival for enalapril-folic acid vs enalapril alone, by utilizing data from 19,053 participants of the CSPPT. Findings revealed a modest gain in lifetime stroke-free survival in relation to enalapril plus folic acid treatment vs enalapril alone among hypertensive patients. In addition, this treatment strategy afforded significant benefit in terms of greater gain in stroke-free survival in certain subgroups, including younger, male patients, those with lower baseline folate concentrations, higher baseline systolic blood pressure, higher baseline total cholesterol and blood glucose, and with MTHFR (methylenetetrahydrofolate reductase) C677T CT or TT genotype.